Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.07)
# 3,358
Out of 4,805 analysts
96
Total ratings
29.49%
Success rate
-18.9%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $3.06 | +96.08% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $19.22 | +134.13% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $38.62 | +117.50% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $101.40 | +8.48% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $34.46 | +10.27% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $12.24 | +22.55% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $57.70 | -8.15% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.38 | +320.17% | 4 | Dec 13, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $33.67 | +107.90% | 2 | Nov 7, 2024 | |
| EPIX ESSA Pharma | Downgrades: Neutral | $15 → $2 | $1.52 | +31.58% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.73 | +998.27% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $3.97 | +378.59% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $1.42 | +956.34% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.38 | +900.00% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $2.46 | +93.09% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $18.54 | +94.17% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.76 | +491.72% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $6.41 | +134.19% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $8.81 | +297.28% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2.25 → $3.5 | $0.49 | +607.64% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.68 | +562.45% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.53 | +1,860.78% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.19 | +1,580.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $0.67 | +1,383.24% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.30 | +1,289.96% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $0.90 | +2,677.78% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.45 | -28.57% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $21.45 | -6.76% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $0.64 | +134.82% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.32 | +3,067.56% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $3.98 | +779.40% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.03 | +5,725.24% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.88 | +525.00% | 3 | Apr 7, 2020 |
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.06
Upside: +96.08%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $19.22
Upside: +134.13%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $38.62
Upside: +117.50%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $101.40
Upside: +8.48%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $34.46
Upside: +10.27%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $12.24
Upside: +22.55%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $57.70
Upside: -8.15%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.38
Upside: +320.17%
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $33.67
Upside: +107.90%
ESSA Pharma
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.52
Upside: +31.58%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.73
Upside: +998.27%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $3.97
Upside: +378.59%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $1.42
Upside: +956.34%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.38
Upside: +900.00%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $2.46
Upside: +93.09%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $18.54
Upside: +94.17%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.76
Upside: +491.72%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $6.41
Upside: +134.19%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $8.81
Upside: +297.28%
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $0.49
Upside: +607.64%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.68
Upside: +562.45%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.53
Upside: +1,860.78%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.19
Upside: +1,580.67%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $0.67
Upside: +1,383.24%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $1.30
Upside: +1,289.96%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $0.90
Upside: +2,677.78%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.45
Upside: -28.57%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $21.45
Upside: -6.76%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $0.64
Upside: +134.82%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.32
Upside: +3,067.56%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $3.98
Upside: +779.40%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.03
Upside: +5,725.24%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.88
Upside: +525.00%